Profile data is unavailable for this security.
About the company
NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.
- Revenue in AUD (TTM)2.39m
- Net income in AUD324.21k
- Incorporated2002
- Employees--
- LocationNeuroScientific Biopharmaceuticals LtdSuite 5, 85 Forrest St, CottesloeNEDLANDS 6011AustraliaAUS
- Phone+61 86382-1800
- Fax+61 86382-1801
- Websitehttps://neuroscientific.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPH Global Ltd | 109.97k | -1.98m | 1.19m | 31.00 | -- | -- | -- | 10.82 | -0.0068 | -0.0093 | 0.0004 | -0.0035 | 0.1252 | 3.72 | 1.82 | -- | -246.30 | -71.38 | -- | -157.22 | 16.61 | 16.85 | -1,966.97 | -150.31 | 0.1376 | -84.10 | -- | -- | 32,244.12 | -41.18 | 53.58 | -- | -- | -- |
| Wellfully Ltd | 1.31m | -1.34m | 1.48m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
| Hexima Ltd | 61.67k | -933.87k | 2.17m | -- | -- | 0.1075 | -- | 35.21 | -0.0559 | -0.0559 | 0.0037 | 0.121 | 0.0236 | -- | 0.1523 | -- | -35.74 | -74.86 | -38.89 | -189.88 | -- | -- | -1,514.30 | -274.35 | -- | -- | 0.00 | -- | -95.85 | -55.24 | 51.33 | -- | -- | -- |
| Vectus Biosystems Ltd | 76.86k | -2.34m | 4.26m | -- | -- | 2.86 | -- | 55.43 | -0.044 | -0.044 | 0.0014 | 0.0279 | 0.0231 | -- | 0.0638 | -- | -70.26 | -84.62 | -88.42 | -227.56 | -- | -- | -3,042.06 | -12,407.49 | 3.45 | -389.35 | 0.00 | -- | 38.46 | 222.59 | 32.07 | -- | -- | -- |
| Holista Colltech Limited | 5.46m | -4.64m | 4.29m | 3.00 | -- | -- | -- | 0.7851 | -0.0166 | -0.0166 | 0.0196 | -0.0094 | 1.48 | 3.54 | 5.39 | -- | -125.43 | -42.59 | -1,528.79 | -63.58 | 51.69 | 56.37 | -85.04 | -39.27 | 0.2094 | -282.55 | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
| Cambium Bio Ltd | 128.99k | -2.26m | 4.89m | -- | -- | 1.76 | -- | 37.92 | -0.4599 | -0.4599 | 0.0173 | 0.2327 | 0.0318 | -- | 1.00 | -- | -55.60 | -30.97 | -144.62 | -99.20 | 62.39 | -- | -1,748.79 | -74.07 | -- | -149.70 | 0.1443 | -- | -- | -- | -33.72 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 2.39m | 324.21k | 5.49m | -- | 16.74 | 1.03 | 13.22 | 2.30 | 0.0023 | 0.0023 | 0.0165 | 0.037 | 0.4458 | -- | 48.82 | -- | 6.04 | -46.72 | 6.46 | -51.16 | -- | -- | 13.56 | -199.33 | -- | 33.42 | 0.00 | -- | -52.76 | 82.13 | 130.34 | -- | -37.50 | -- |
| Avecho Biotechnology Ltd | 339.30k | -3.48m | 6.34m | 29.00 | -- | 1.50 | -- | 18.68 | -0.0012 | -0.0012 | 0.0001 | 0.0013 | 0.0693 | 4.26 | 0.7043 | -- | -71.20 | -47.08 | -105.46 | -55.25 | -45.60 | 78.67 | -1,026.91 | -156.43 | 3.48 | -- | 0.0316 | -- | -58.07 | -19.42 | -46.71 | -- | -- | -- |
| Invex Therapeutics Ltd | 1.70m | -1.64m | 6.76m | -- | -- | 1.19 | -- | 3.97 | -0.0218 | -0.0218 | 0.0227 | 0.0757 | 0.1178 | -- | 7.95 | -- | -11.35 | -15.73 | -12.20 | -16.55 | -- | -- | -96.35 | -535.37 | -- | -- | 0.00 | -- | 35.66 | 566.05 | 78.81 | -- | -- | -- |
| Zelira Therapeutics Ltd | 1.02m | -36.57m | 7.94m | 8.00 | -- | -- | -- | 7.76 | -3.22 | -3.22 | 0.0902 | -0.3979 | 0.0524 | 0.0609 | 5.06 | -- | -188.05 | -46.98 | -246.20 | -50.16 | 91.73 | -- | -3,587.90 | -1,063.82 | 0.424 | -6.78 | 3.35 | -- | -82.72 | -35.59 | -556.18 | -- | -- | -- |
| Patrys Ltd | 1.39m | -3.54m | 8.23m | 15.00 | -- | 2.37 | -- | 5.90 | -0.0017 | -0.0017 | 0.0007 | 0.0017 | 0.2386 | -- | 0.6665 | -- | -60.57 | -52.81 | -68.65 | -56.79 | -- | -- | -253.86 | -249.64 | -- | -- | 0.00 | -- | -51.11 | 10.55 | 49.88 | -- | -4.41 | -- |
| Chimeric Therapeutics Ltd | 0.00 | -12.53m | 9.95m | -- | -- | 3.55 | -- | -- | -0.0136 | -0.0136 | 0.00 | 0.0028 | 0.00 | -- | -- | -- | -66.56 | -- | -194.88 | -- | -- | -- | -- | -- | -- | -58.48 | 0.5228 | -- | -- | -- | 51.65 | -- | -- | -- |
